Fresenius Kabi Launches Single-Needle Option for the Amicus® Extracorporeal Photopheresis Protocol
23.4.2023 10:00:00 EEST | Business Wire | Press release
Fresenius Kabi today announced the availability of a single-needle venous access option for the Amicus® Extracorporeal Photopheresis (ECP) System at the 49th annual meeting of the European Society for Blood and Marrow Transplantation (EBMT).
Fresenius Kabi is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition.
The Amicus Blue System with online ECP was launched in Europe in 2019 with double-needle venous access only. The update announced today includes new software v6.1 for the Amicus Separator, new software v2.1 for the Phelix Photoactivation Device and a new single-use disposable kit that can be configured for single or double-needle venous access. The system also allows clinicians to switch between single and double-needle access at any time during the procedure.
“We are thrilled to enable the single-needle option for the Amicus Blue ECP system, which will allow physicians to treat patients with limited venous access. This builds on our Amicus Blue vision to provide a versatile, multi-procedural instrument to support patients’ individual needs,” said Christian Hauer, President Fresenius Kabi MedTech.
The Amicus ECP System has obtained CE mark for the indication of CTCL in the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL) that is unresponsive to other forms of treatment. The Amicus ECP System is CE marked in compliance with the applicable requirements of the Medical Device Regulation (EU) 2017/745 and includes:
- Amicus Separator
- Phelix Photoactivation Device
- Amicus ECP Apheresis Kits
Amicus Separator is also cleared in Europe and the United States for therapeutic plasma exchange (TPE), red blood cell exchange (RBCx), mononuclear cell (MNC) collection and platelet collection. The Amicus ECP System is not cleared for use in the U.S.
Not all products listed are available or approved for sale in all countries. Contact your local Fresenius Kabi representative for additional information and product availability. Refer to the Amicus Separator Operator’s Manual and Phelix Photoactivation Device Operator’s Manual for a complete list of warnings and precautions associated with the use of these products.
About Extracorporeal Photopheresis
Extracorporeal photopheresis or ECP is a leukapheresis-based therapeutic procedure. The technology is currently approved for the treatment of cutaneous T-cell lymphoma (CTCL). Literature shows that it has also been used for graft versus host disease (GvHD) following bone marrow or stem cell transplant, the rejection of solid organ transplants, and autoimmune diseases where cell-mediated mechanisms are dominant.
An online ECP procedure involves collection of mononuclear cells from the patient, treatment of collected cells with a light sensitive drug, 8-methoxypsoralen and exposure of cells to UV-A light, followed by the reinfusion of treated cells back to the patient. After reinfusion, the treated cells become apoptotic and are believed to be taken up by antigen presenting cells resulting in an immune response. The online ECP process combines cell separation and photoactivation into a single, sterile circuit reducing the risk of infection and cross-contamination.
About Cutaneous T-cell Lymphoma
Cutaneous T-cell lymphomas are a heterogenous group of T-cell lymphoproliferative disorders involving the skin, the most common variants classified as Mycosis Fungoides (MF) or Sézary Syndrome (SS). Patients may experience itchy, scaly patches or plaques of the skin. As the disease progresses, some patients may experience growth of nodular lesions and large tumors, and internal organ involvement. Treatment is palliative, with the aim to induce long-term remissions and improve patient quality of life.
About Fresenius Kabi
Fresenius Kabi (www.fresenius-kabi.com) is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. The company’s global headquarters is in Bad Homburg, Germany.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230423005002/en/
Contact information
Dolores Juarez
+49 152 563 86727
dolores.juarez@fresenius-kabi.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New ECCO data show subcutaneous (SC) infliximab (Remsima ™ SC) effectively recaptures and maintains disease control after drug holiday16.2.2026 09:00:00 EET | Press release
Celltrion, Inc. today announced new data from a post-hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC), showing that subcutaneous (SC) infliximab restored and maintained response in most Crohn’s disease (CD) and ulcerative colitis (UC) patients with sustained efficacy, safety, and persistence through to Week 102.1 The data will be presented as a poster presentation at the 21st Congress of the European Crohn’s and Colitis Organisation (ECCO), to be held from February 18-21 in Stockholm, Sweden. “As immunogenicity is the most significant concern when restarting treatment with infliximab after an interruption, these results suggest that treatment persistence was maintained even in patients with immunogenicity,” said Dr. Marla Dubinsky, Professor of Pediatrics and Director of the IBD Center at the Icahn School of Medicine at Mount Sinai. “It's reassuring to see that not only can we effectively recapture disease control with a convenient subcutaneous option, but that t
Galderma Announces Appointment of New Chief Financial Officer16.2.2026 08:00:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the appointment of Luigi La Corte as Chief Financial Officer (CFO), effective May 1, 2026. Luigi La Corte will join Galderma on April 1 to begin a smooth and orderly transition with Thomas Dittrich, who has served as CFO of Galderma since October 2019. As previously announced, Thomas will remain with the company through Q2 2026 to ensure a seamless transition before pursuing another senior executive opportunity outside the organization. “Luigi La Corte is an accomplished financial leader with deep experience across global healthcare and consumer organizations. I am delighted to welcome him to the Executive Committee and look forward to working with him closely as we continue to execute our Integrated Dermatology Strategy and extend our category leadership in dermatology. I would also like to thank Thomas for his commitment to ensuring a seamless transition and his many contributions to Galderma dur
REJO brings CUBE modular device to Japan in its global premiere16.2.2026 04:00:00 EET | Press release
REJO, a pioneering global provider of heat-not-burn (HNB) solutions, today announced the global debut of REJO CUBE, its latest modular HNB device, in Japan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260215596376/en/ REJO CUBE DEVICE-Product Infographic Breaking away from conventional HNB design norms, REJO CUBE introduces a bold new device option featuring a trendy design and dual-mode inhalation experience, launching on Japan’s major e-commerce retail channels from February 16. This launch marks the brand’s latest move following REJO Mate Air’s introduction in Japan in July 2025, when the device’s compact design, smooth mouthfeel, and Puff Twice feature won widespread acclaim among local adult users. REJO CUBE speak for REJO’s ongoing commitment to placing user experience at the core of its research and development effort, bringing kit flexibility with modular design, deep user engagement with interactive features, and
Sultan bin Ahmed Visits Shanghai Film Studios, Film Park and Stadium15.2.2026 21:24:00 EET | Press release
His Highness Sheikh Sultan bin Ahmed bin Sultan Al Qasimi, Deputy Ruler of Sharjah and Chairman of the Sharjah Media Council, visited the 800,000-square-metre Shanghai Film Studios and Film Park in the town of Shidon in the Chinese city of Shanghai on Saturday. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260215440594/en/ Sultan bin Ahmed visits Shanghai Film Studios, Film Park and Stadium (Photo: AETOSWire) His Highness watched a video outlining the specifications of the Shanghai studios, which comprise 4 professional studios ranging in size from 800 to 3000 square metres, a large costume warehouse, production support facilities, classic cars, and an integrated set of production services. His Highness was briefed on the work produced using artificial intelligence technologies. He toured the sound recording rooms, image quality control, editing and post-production facilities, and listened to an explanation on the developme
Estithmar Holding Establishes “Estithmar Capital” for Financial Investment Management15.2.2026 19:45:00 EET | Press release
Estithmar Holding Q.P.S.C. announced today the establishment of its fifth group, “Estithmar Capital,” in a strategic step aimed at strengthening the company’s expansion and diversifying the sectors in which it operates. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260215458570/en/ Estithmar Holding Establishes “Estithmar Capital” for Financial Investment Management (Photo: AETOSWire) Estithmar Capital will specialize in managing financial investments, strengthening institutional governance, and operating under clear frameworks for compliance, regulation, and risk management, reflecting Estithmar Holding’s vision for sustainability and responsible, well-structured growth. The establishment of Estithmar Capital supports Estithmar Holding’s broader strategy of diversifying financial assets, improving capital efficiency, and unifying governance practices across various markets. Through a centralized and disciplined approach, t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom